ArticleClinical and vaccine immunology : CVI2013
Invasive and noninvasive Streptococcus pneumoniae capsule and surface protein diversity following the use of a conjugate vaccine.
Article in Clinical and vaccine immunology : CVI, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Invasive pneumococcal disease in the Gulf region: a narrative review of incidence, burden, and vaccine strategies.Frontiers in public health · 2025Review
- Article
- Fourier transform infrared spectroscopy forFrontiers in microbiology · 2024Article
- Serotype Distribution and Antimicrobial Resistance ofAnnals of laboratory medicine · 2023Article
- Article
- A Multicenter Evaluation of Trends in Antimicrobial Resistance AmongOpen forum infectious diseases · 2022Article
- Molecular Characterization of Predominant Serotypes, Drug Resistance, and Virulence Genes ofFrontiers in microbiology · 2022Article
- Transition of Serotype 35B Pneumococci From Commensal to Prevalent Virulent Strain in Children.Frontiers in cellular and infection microbiology · 2021Article
- The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA.mSphere · 2019Article
- Progress toward a group B streptococcal vaccine.Human vaccines & immunotherapeutics · 2018Article
- Emergence of Multidrug-Resistant Pneumococcal Serotype 35B among Children in the United States.Journal of clinical microbiology · 2017Article
- Role ofFrontiers in microbiology · 2017Review
- Review
- Immunization with Pneumococcal Surface Protein K of Nonencapsulated Streptococcus pneumoniae Provides Protection in a Mouse Model of Colonization.Clinical and vaccine immunology : CVI · 2015Article
- Pneumococcal PspA and PspC proteins: potential vaccine candidates for experimental otitis media.International journal of pediatric otorhinolaryngology · 2014Article
- Promises and pitfalls of live attenuated pneumococcal vaccines.Human vaccines & immunotherapeutics · 2014Article
- Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae causing noninvasive diseases in a Children's Hospital, Shanghai.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in the United States in 2010 for the prevention of invasive pneumococcal disease (IPD) and otitis media. While many studies have reported its potential efficacy for IPD, not much is known about the epidemiology of noninvasive disease following its introduction. We characterized the capsular types and surface protein genes of noninvasive pediatric pneumococcal isolates collected between 2002 and 2010 (n = 1,058) at Children's of Alabama following the introduction of PCV7 and tested a subset of noninvasive and previously characterized IPD isolates for the presence of the pspA, pspC, and rrgC genes, which encode protection-eliciting proteins. PCV7 serotypes had dramatically decreased by 2010 (P < 0.0001), and only 50% of all noninvasive infections were caused by the PCV13 capsular serotypes. Serotype 19A accounted for 32% of the noninvasive isolates, followed by serotypes 35B (9%), 19F (7%), and 6C (6%). After 7 years of PCV7 usage, there were no changes in the frequencies of the pspA or pspC genes; 96% of the strains were positive for family 1 or 2 pspA genes, and 81% were also positive for pspC. Unexpectedly, more noninvasive than invasive strains were positive for rrgC (P < 0.0001), and the proportion of rrgC-positive strains in 2008 to 2010 was greater than that in 2002 to 2008 (IPD, P < 0.02; noninvasive, P < 0.001). Serotypes 19F, 19A, and 35B were more frequently rrgC positive (P < 0.005) than other serotypes. A vaccine containing antigens, such as PspA, PspC, and/or RrgC, can provide coverage against most non-PCV13-type pneumococci. Continued surveillance is critical for optimal future vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.